Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials
- 22 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (21) , e2378-e2384
Abstract
Background and Objectives The use of surrogate end points can decrease sample size while maintaining statistical power. This report considers incident stroke symptoms as a surrogate end point in a post hoc analysis of asymptomatic patients from the multicenter, randomized Carotid Revascularization Endarterectomy vs Stenting Trial (CREST). Methods CREST assessed stroke symptoms using the Questionnaire for Verifying Stroke-free Status (QVSS) at baseline and follow-up. While the primary analysis of CREST defined “asymptomatic” as having been free of stroke/transient ischemic attack for 180 days, herein the population was further restricted by requiring no stroke symptoms at baseline. Incident adjudicated stroke was defined the same as for the primary analysis; incident stroke symptoms was defined as developing ≥1 stroke symptom in follow-up. Treatment differences between stenting (CAS) and endarterectomy (CEA) were assessed for 3 end points: adjudicated stroke, stroke symptoms, and adjudicated stroke or stroke symptoms. Results The cohort included 826 of the 1,181 asymptomatic patients in CREST. Adjudicated stroke events occurred in 44 patients, and incident stroke symptoms occurred in 183. Analysis of adjudicated stroke end points demonstrated a nonsignificant hazard ratio (HR) for CAS compared with CEA of 1.02 (95% CI 0.57–1.85). The corresponding HR for the incident stroke symptoms outcome was 1.54 (95% CI 1.15–2.08), and the HR for the composite outcome of adjudicated stroke or incident symptoms was 1.38 (95% CI 1.04–1.83), both significant. Discussion The low stroke event rates in asymptomatic patients challenges the assessment of CAS-versus-CEA treatment differences. Incorporating incident stroke symptoms as a surrogate outcome increased the number of events by over 4-fold. The analysis demonstrated a previously unreported significant difference in cerebrovascular risk with CAS compared with CEA. We propose that broadening the end points of primary stroke prevention trials to include surrogate events such as incident stroke symptoms could make trials more feasible.Keywords
This publication has 28 references indexed in Scilit:
- Self-Report of Stroke, Transient Ischemic Attack, or Stroke Symptoms and Risk of Future Stroke in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) StudyStroke, 2013
- Biomarkers and surrogate endpoints in clinical trialsStatistics in Medicine, 2012
- Self-Reported Stroke Symptoms Without a Prior Diagnosis of Stroke or Transient Ischemic AttackStroke, 2011
- Recruitment and Retention Strategies for Minority or Poor Clinical Research Participants: Lessons From the Healthy Aging in Neighborhoods of Diversity Across the Life Span StudyThe Gerontologist, 2011
- Stenting versus Endarterectomy for Treatment of Carotid-Artery StenosisNew England Journal of Medicine, 2010
- Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST)International Journal of Stroke, 2010
- Stroke Symptoms in Individuals Reporting No Prior Stroke or Transient Ischemic Attack Are Associated With a Decrease in Indices of Mental and Physical FunctioningStroke, 2007
- Reliability of the Questionnaire for Verifying Stroke-Free StatusCerebrovascular Diseases, 2003
- Verifying the Stroke-Free Phenotype by Structured Telephone InterviewStroke, 2000
- A Randomized, Double-Blind Study of Phenytoin for the Prevention of Post-Traumatic SeizuresNew England Journal of Medicine, 1990